309 related articles for article (PubMed ID: 18037524)
1. Potential of dose optimisation in MRI-based PDR brachytherapy of cervix carcinoma.
De Brabandere M; Mousa AG; Nulens A; Swinnen A; Van Limbergen E
Radiother Oncol; 2008 Aug; 88(2):217-26. PubMed ID: 18037524
[TBL] [Abstract][Full Text] [Related]
2. MRI-guided treatment-planning optimisation in intracavitary or combined intracavitary/interstitial PDR brachytherapy using tandem ovoid applicators in locally advanced cervical cancer.
Jürgenliemk-Schulz IM; Tersteeg RJ; Roesink JM; Bijmolt S; Nomden CN; Moerland MA; de Leeuw AA
Radiother Oncol; 2009 Nov; 93(2):322-30. PubMed ID: 19748695
[TBL] [Abstract][Full Text] [Related]
3. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer.
Kirisits C; Pötter R; Lang S; Dimopoulos J; Wachter-Gerstner N; Georg D
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):901-11. PubMed ID: 15936576
[TBL] [Abstract][Full Text] [Related]
4. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
Fokdal L; Tanderup K; Nielsen SK; Christensen HK; Røhl L; Pedersen EM; Schønemann NK; Lindegaard JC
Radiother Oncol; 2011 Sep; 100(3):473-9. PubMed ID: 21924784
[TBL] [Abstract][Full Text] [Related]
5. A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer.
Yoshida K; Yamazaki H; Takenaka T; Kotsuma T; Yoshida M; Furuya S; Tanaka E; Uegaki T; Kuriyama K; Matsumoto H; Yamada S; Ban C
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):765-72. PubMed ID: 19836165
[TBL] [Abstract][Full Text] [Related]
6. Intercomparison of treatment concepts for MR image assisted brachytherapy of cervical carcinoma based on GYN GEC-ESTRO recommendations.
Lang S; Nulens A; Briot E; Kirisits C; De Brabandere M; Dumas I; Dimopoulos J; Petrow P; Georg D; Van Limbergen E; Haie-Meder C; Pötter R
Radiother Oncol; 2006 Feb; 78(2):185-93. PubMed ID: 16466820
[TBL] [Abstract][Full Text] [Related]
7. From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer.
Tanderup K; Nielsen SK; Nyvang GB; Pedersen EM; Røhl L; Aagaard T; Fokdal L; Lindegaard JC
Radiother Oncol; 2010 Feb; 94(2):173-80. PubMed ID: 20138380
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix.
Zwahlen D; Jezioranski J; Chan P; Haider MA; Cho YB; Yeung I; Levin W; Manchul L; Fyles A; Milosevic M
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1157-64. PubMed ID: 19101097
[TBL] [Abstract][Full Text] [Related]
9. Uncertainties when using only one MRI-based treatment plan for subsequent high-dose-rate tandem and ring applications in brachytherapy of cervix cancer.
Kirisits C; Lang S; Dimopoulos J; Oechs K; Georg D; Pötter R
Radiother Oncol; 2006 Dec; 81(3):269-75. PubMed ID: 17126938
[TBL] [Abstract][Full Text] [Related]
10. Determining DVH parameters for combined external beam and brachytherapy treatment: 3D biological dose adding for patients with cervical cancer.
Van de Kamer JB; De Leeuw AA; Moerland MA; Jürgenliemk-Schulz IM
Radiother Oncol; 2010 Feb; 94(2):248-53. PubMed ID: 20080309
[TBL] [Abstract][Full Text] [Related]
11. A comparison of ICRU point doses and volumetric doses of organs at risk (OARs) in brachytherapy for cervical cancer.
Vinod SK; Caldwell K; Lau A; Fowler AR
J Med Imaging Radiat Oncol; 2011 Jun; 55(3):304-10. PubMed ID: 21696566
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.
Pötter R; Dimopoulos J; Georg P; Lang S; Waldhäusl C; Wachter-Gerstner N; Weitmann H; Reinthaller A; Knocke TH; Wachter S; Kirisits C
Radiother Oncol; 2007 May; 83(2):148-55. PubMed ID: 17531904
[TBL] [Abstract][Full Text] [Related]
13. Applicator reconstruction and applicator shifts in 3D MR-based PDR brachytherapy of cervical cancer.
De Leeuw AA; Moerland MA; Nomden C; Tersteeg RH; Roesink JM; Jürgenliemk-Schulz IM
Radiother Oncol; 2009 Nov; 93(2):341-6. PubMed ID: 19515443
[TBL] [Abstract][Full Text] [Related]
14. Treatment planning for MRI assisted brachytherapy of gynecologic malignancies based on total dose constraints.
Lang S; Kirisits C; Dimopoulos J; Georg D; Pötter R
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):619-27. PubMed ID: 17869676
[TBL] [Abstract][Full Text] [Related]
15. Pilot study in the treatment of endometrial carcinoma with 3D image-based high-dose-rate brachytherapy using modified Heyman packing: clinical experience and dose-volume histogram analysis.
Weitmann HD; Pötter R; Waldhäusl C; Nechvile E; Kirisits C; Knocke TH
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):468-78. PubMed ID: 15890589
[TBL] [Abstract][Full Text] [Related]
16. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer.
Lindegaard JC; Tanderup K; Nielsen SK; Haack S; Gelineck J
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):756-64. PubMed ID: 18191335
[TBL] [Abstract][Full Text] [Related]
17. Point vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.
Yaparpalvi R; Mutyala S; Gorla GR; Butler J; Mah D; Garg MK; Kalnicki S
Brachytherapy; 2008; 7(4):336-42. PubMed ID: 18782683
[TBL] [Abstract][Full Text] [Related]
18. Correlation between the treated volume, the GTV and the CTV at the time of brachytherapy and the histopathologic findings in 33 patients with operable cervix carcinoma.
Muschitz S; Petrow P; Briot E; Petit C; De Crevoisier R; Duvillard P; Morice P; Haie-Meder C
Radiother Oncol; 2004 Nov; 73(2):187-94. PubMed ID: 15542166
[TBL] [Abstract][Full Text] [Related]
19. A dose planning study on applicator guided stereotactic IMRT boost in combination with 3D MRI based brachytherapy in locally advanced cervical cancer.
Assenholt MS; Petersen JB; Nielsen SK; Lindegaard JC; Tanderup K
Acta Oncol; 2008; 47(7):1337-43. PubMed ID: 18663651
[TBL] [Abstract][Full Text] [Related]
20. The effect of alternative biological modelling parameters (α/β and half time of repair T ½ ) on reported EQD2 values in the treatment of advanced cervical cancer.
De Leeuw AA; Van de Kamer JB; Moerland MA; Philippens ME; Jürgenliemk-Schulz IM
Radiother Oncol; 2011 Nov; 101(2):337-42. PubMed ID: 21742393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]